Physician profile
Ashley E Green
NPI 1538697586
$1,668.55
in general payments reported to CMS, 2019-2025
17 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $482 · 2024: $832 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100 · Consulting Fee: $64.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
| Consulting Fee | $64.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $405.05 | 2024-2025 | |
| Lundbeck LLC | $185.92 | 2023-2024 | Vyepti |
| Alexion Pharmaceuticals, INC. | $177.45 | 2024 | Ultomiris |
| Lilly USA, LLC | $154.96 | 2024-2025 | Omvoh, Kisunla |
| Horizon Therapeutics Plc | $124.50 | 2023 | Tepezza |
| Genzyme Corporation | $100.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.21 | 2023 | Entyvio, Hyqvia, Glassia |
| Astrazeneca Pharmaceuticals LP | $72.24 | 2023-2025 | Saphnelo, Tezspire |
| Adma Biomanufacturing LLC | $64.86 | 2023-2024 | |
| Inspire Medical Systems, INC. | $58.78 | 2023-2024 | Inspire |
| Abbvie INC. | $58.67 | 2024-2025 | |
| Janssen Biotech, INC. | $46.77 | 2025 | Tremfya, Simponi Aria, Remicade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.94 | 2023-2024 | Jardiance, Spevigo |
| Novartis Pharmaceuticals Corporation | $31.43 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $27.91 | 2023 | Truxima |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.61 | 2025 | |
| Eisai INC. | $14.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.